<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02009631</url>
  </required_header>
  <id_info>
    <org_study_id>M12-020</org_study_id>
    <secondary_id>2013-002028-18</secondary_id>
    <nct_id>NCT02009631</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors</brief_title>
  <official_title>A Randomized, Placebo-Controlled Crossover Study to Evaluate the Effect of Veliparib (ABT-888) on Cardiac Repolarization in Subjects With Relapsed or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized Phase 1 study to evaluate the effects of Veliparib on cardiac
      repolarization in patients with solid tumors who's cancer has recurred or is no longer
      responding to current treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effect of Veliparib on corrected QT interval calculated by Fridericia's formula (QTcF)</measure>
    <time_frame>Electrocardiograms (ECGs) will be done at Screening, 6 time points on Day 1 of Periods 1, 2 and 3 in triplicate, 1 time point on Day 2 of Periods 1, 2, and 3 and 1 time point on Day 3 of Period 3.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic sampling maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Pharmacokinetic samples will be drawn at Screening, 6 time points on Day 1 of Periods 1, 2 and 3 and 1 time point on Day 2 of Periods 1, 2, and 3.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic sampling - time to maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Pharmacokinetic samples will be drawn at Screening, 6 time points on Day 1 of Periods 1, 2 and 3 and 1 time point on Day 2 of Periods 1, 2, and 3.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic sampling - the area under the plasma concentration-time curve (AUC) from time 0-24 hours (AUC 0-24)</measure>
    <time_frame>Pharmacokinetic samples will be drawn at Screening, 6 time points on Day 1 of Periods 1, 2 and 3 and 1 time point on Day 2 of Periods 1, 2, and 3.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of subjects with adverse events</measure>
    <time_frame>Up to 30 days after last dose of study drug.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Up to 30 days after last dose of study drug.</time_frame>
    <description>Blood pressure, heart rate and temperature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Tests</measure>
    <time_frame>Up to 30 days after last dose of study drug.</time_frame>
    <description>Hematology, chemistry, urinalysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Assessment</measure>
    <time_frame>Screening</time_frame>
    <description>A computerized tomography scan will be done at screening to document tumor size.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Colon Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Sequence Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg Veliparib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg Veliparib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence Group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Veliparib (ABT-888)</intervention_name>
    <arm_group_label>Sequence Group A</arm_group_label>
    <arm_group_label>Sequence Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Sequence Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed solid malignancy that is metastatic or unresectable for which standard
             curative measures or other therapy that may provide clinical benefit do not exist or
             are no longer effective.

          -  Subjects with brain metastases must have clinically controlled neurologic symptoms.

          -  Subject is able to swallow and retain oral medications and does not have uncontrolled
             emesis.

          -  Subject has adequate bone marrow, renal and hepatic function per local laboratory
             reference ranges.

        Exclusion Criteria:

          -  Uncorrected serum potassium, serum magnesium, serum calcium or free thyroxin (FT4) and
             thyroid stimulating hormone (TSH) outside of normal reference ranges, or grade 2
             hyponatremia or hypernatremia.

          -  Subject has severe ECG morphologic abnormalities that make QTc evaluation difficult.

          -  Subject has a history of cardiac conduction abnormalities.

          -  Subject has a significant history of cardiovascular disease.

          -  Subject has received any anti-cancer therapies 21 days prior to the first dose of
             study drug, or has recovered to no better than a grade 2 or higher clinically
             significant adverse effect(s)/toxicity(s) of the previous therapy.

          -  Use of drugs with a known risk for QT prolongation and Torsades de Pointes within 7
             days prior to the first study dose.

          -  Use of tobacco or nicotine-containing products within 12 hours prior to the first
             study dose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stacie Shepherd, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116015</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 116016</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 117320</name>
      <address>
        <city>Groningn</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 117336</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 117517</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Munasinghe W, Stodtmann S, Tolcher A, Calvo E, Gordon M, Jalving M, de Vos-Geelen J, Medina D, Bergau D, Nuthalapati S, Hoffman D, Shepherd S, Xiong H. Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study. Cancer Chemother Pharmacol. 2016 Nov;78(5):1003-1011. Epub 2016 Oct 5.</citation>
    <PMID>27709282</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2013</study_first_submitted>
  <study_first_submitted_qc>December 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2013</study_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Colon Cancer</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Gastric Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Veliparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

